Comprehensive Translational Medicine
CDO Enabling Drug R&D
A Leader of Companion Diagnostics Total-Solution Providers
Patient Testing for Precision Medicine
State-of-Art Facilities & Global-standard Quality Systems
Translational Medicine
MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.
Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.
We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take
Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored
Introduction The study of cancer has been extended from single genes to macrogenes, and from sing
view more >>
view more >>
view more >>
view more >>
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests tha
A recent study has demonstrated that a precision medicine approach improves treatment selection for
C-S disulfide variants exhibit the same trend in agonistic activity and conformation in anti-hCD40 a
Metastatic tumor cells traveling in the bloodstream as clusters, shown here as a pair of cells, larg
Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospi
Somewhere in the body of a patient, a small clump of cells, growing undetected, has begun to form a
A team of researchers from the University of Chicago, in collaboration with researchers from the Uni
A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhi